Class summary at a glance.

Every drug in the Amide Local Anesthetic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 23tracked in Part D
CY24 Part D spend: $350.5Mcombined across class
Total Rx claims: 3.6M1.6M unique beneficiaries
Generic mfrs (active): 47across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Lidocaine

Brand: Accucaine · 3.6M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 1972-02-14

18 generic mfrs 1079 plans require PA Discontinued

Low NADAC$0.068

→

Avg plan cost$0.652

Part D spend $350.5M 10× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Bupivacaine

Brand: Bupivacine HCl · 335 Part D claims (CY24) · 187 beneficiaries · First FDA approval: 2005-03-31

10 generic mfrs Active FDA shortage

Low NADAC$0.048

→

Avg plan cost$0.065

Part D spend $6882 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Bupivacaine and Epinephrine

Brand: Marcaine with Epinephrine · — Part D claims (CY24) · First FDA approval: 2005-05-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Bupivacaine and Epinephrine Bitartrate

Brand: MARCAINE WITH EPINEPHRINE · — Part D claims (CY24) · First FDA approval: 2005-09-12

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Bupivacaine and Meloxicam

Brand: ZYNRELEF · — Part D claims (CY24) · First FDA approval: 2021-07-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Collavera

— Part D claims (CY24) · First FDA approval: 2026-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidexa

— Part D claims (CY24) · First FDA approval: 2026-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine Patch

Brand: LIDODERM · — Part D claims (CY24) · First FDA approval: 2022-10-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine and Capsaicin

Brand: Trubrexa · — Part D claims (CY24) · First FDA approval: 2023-10-03

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine and Diclofenac

Brand: Diclona Gel · — Part D claims (CY24) · First FDA approval: 2023-01-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine and Menthol

Brand: LIDOTHOL · — Part D claims (CY24) · First FDA approval: 2023-09-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine and Prilocaine

Brand: Cadira Compliant Blood Stat · — Part D claims (CY24) · First FDA approval: 2003-08-18

Brand-only (no generics) 185 plans require PA

Low NADAC$0.239

→

Avg plan cost$0.522

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lidocaine and Tetracaine

Brand: PLIAGLIS · — Part D claims (CY24) · First FDA approval: 2026-03-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine, Capsaicin, Menthol, Methyl Salicylate

Brand: 1ST MEDXPATCH · — Part D claims (CY24) · First FDA approval: 2018-03-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine, Menthol

Brand: Gen7T Plus · — Part D claims (CY24) · First FDA approval: 2020-07-29

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine, Prilocaine

Brand: LIDO BDK · — Part D claims (CY24) · First FDA approval: 2003-08-27

5 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidomax

— Part D claims (CY24) · First FDA approval: 2026-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidothol Patch

— Part D claims (CY24) · First FDA approval: 2024-05-28

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidovara

— Part D claims (CY24) · First FDA approval: 2026-02-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Menthol

Brand: Lidothol ES · — Part D claims (CY24) · First FDA approval: 2026-01-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Mepivacaine

Brand: Carbocaine · — Part D claims (CY24) · First FDA approval: 1984-10-10

2 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ropivacaine

Brand: NAROPIN · — Part D claims (CY24) · First FDA approval: 1996-09-24

12 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Trubrexa Patch Er

— Part D claims (CY24) · First FDA approval: 2024-03-11

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.